Gopal MBBS - Rezolute Senior Development
| RZLT Stock | USD 4.99 0.20 4.18% |
Executive
Gopal MBBS is Senior Development of Rezolute
| Address | 275 Shoreline Drive, Redwood City, CA, United States, 94065 |
| Phone | 650 206 4507 |
| Web | https://www.rezolutebio.com |
Rezolute Management Efficiency
The company has return on total asset (ROA) of (0.3433) % which means that it has lost $0.3433 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5773) %, meaning that it created substantial loss on money invested by shareholders. Rezolute's management efficiency ratios could be used to measure how well Rezolute manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.54 in 2024. Return On Capital Employed is likely to gain to -0.54 in 2024. At this time, Rezolute's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 139.4 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 69.1 K in 2024.Similar Executives
| Found 13 records | EXECUTIVE Age | ||
| DO Sr | Larimar Therapeutics | 63 | |
| MHS MD | Clene Inc | N/A | |
| Mark ESQ | Clene Inc | 66 | |
| Sr DO | Larimar Therapeutics | 63 | |
| Paul Little | Eledon Pharmaceuticals | 59 | |
| Bryan JD | Eledon Pharmaceuticals | 44 | |
| FACS FACS | Eledon Pharmaceuticals | N/A | |
| Jennifer Johansson | Larimar Therapeutics | N/A | |
| Mary Mcneil | Clene Inc | N/A | |
| John Herberger | Eledon Pharmaceuticals | N/A | |
| John Berman | Larimar Therapeutics | N/A | |
| Jerry JD | Clene Inc | N/A | |
| Gopi MBA | Larimar Therapeutics | 53 | |
Management Performance
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.34 |
Rezolute Leadership Team
Elected by the shareholders, the Rezolute's board of directors comprises two types of representatives: Rezolute inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rezolute. The board's role is to monitor Rezolute's management team and ensure that shareholders' interests are well served. Rezolute's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rezolute's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Raj MD, VP Development | ||
| Michael Deperro, Senior Development | ||
| LLM JD, Chief Officer | ||
| Gopal MBBS, Senior Development | ||
| MD MBA, Director Affairs | ||
| Daron Evans, Chief Officer | ||
| Erin OBoyle, Senior Operations | ||
| Chris Milks, VP Finance | ||
| MS MBA, Chief Officer | ||
| Nevan JD, CEO, Founder | ||
| Robyn Sweinhart, VP Quality | ||
| Brian MD, Chief Officer | ||
| Michael Covarrubias, Senior Management |
Rezolute Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rezolute a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 182.95 M | ||||
| Shares Outstanding | 57.94 M | ||||
| Shares Owned By Insiders | 13.74 % | ||||
| Shares Owned By Institutions | 64.24 % | ||||
| Number Of Shares Shorted | 1.08 M | ||||
| Price To Book | 2.55 X | ||||
| EBITDA | (68.42 M) | ||||
| Net Income | (68.46 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rezolute Stock Analysis
When running Rezolute's price analysis, check to measure Rezolute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rezolute is operating at the current time. Most of Rezolute's value examination focuses on studying past and present price action to predict the probability of Rezolute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rezolute's price. Additionally, you may evaluate how the addition of Rezolute to your portfolios can decrease your overall portfolio volatility.